Quality of care for secondary cardiovascular disease prevention in 2009–2017: population-wide cohort study of antiplatelet therapy use in Scotland
<p><strong>Background:</strong> Antiplatelet therapy (APT) can substantially reduce the risk of further vascular events in individuals with established atherosclerotic cardiovascular disease (ASCVD). However, knowledge regarding the extent and determinants of APT use is li...
主要な著者: | Thalmann, I, Preiss, D, Schlackow, I, Gray, A, Mihaylova, B |
---|---|
フォーマット: | Journal article |
言語: | English |
出版事項: |
BMJ Publishing Group
2023
|
類似資料
-
Antiplatelet therapy use for the secondary prevention of cardiovascular disease in 2009-2017: a population-wide retrospective cohort study of Scotland
著者:: Thalmann, I, 等
出版事項: (2022) -
Population-wide cohort study of statin use for the secondary cardiovascular disease prevention in Scotland in 2009–2017
著者:: Thalmann, I, 等
出版事項: (2022) -
Cholesterol- and blood pressure-lowering drug use for secondary cardiovascular prevention in 2004 - 2013 Europe
著者:: Achelrod, D, 等
出版事項: (2016) -
Determinants of medication use for the secondary prevention of cardiovascular disease
著者:: Thalmann, I
出版事項: (2021) -
Antiplatelets in secondary stroke prevention
著者:: Olga eShulga, 等
出版事項: (2011-07-01)